No stone left unturned

Versant Ventures added to its Canada playbook last week by backing a biotech that has been working in stealth mode to develop an oncolytic virus that is expected to be more potent than first-generation products.

The VC led Turnstone Biologics Inc.'s C$11.3 million ($8.6 million) series A round and set aside an additional C$13.7 million ($10.4 million) in reserve for the company. Seed investor FACIT also participated...